Is the infection of the SARS-CoV-2 Delta variant associated with the outcomes of COVID-19 patients?

Gunadi^{1*}, Mohamad Saifudin Hakim², Hendra Wibawa³, Marcellus⁴, Vivi Setiawaty⁵, Slamet⁶, Ika Trisnawati⁷, Endah Supriyati⁸, Riat El Khair⁹, Kristy Iskandar¹⁰, Afiahayati¹¹, Siswanto¹², Irene¹³, Nungki Anggorowati¹⁴, Edwin Widyanto Daniwijaya¹⁵, Dwi Aris Agung Nugrahaningsih¹⁶, Yunika Puspawati¹⁷, Dyah Ayu Puspitarani¹⁸, Irene Tania¹⁹, Khanza Adzkia Vujira²⁰, Muhammad Buston Ardlyamustaqim²¹, Gita Christy Gabriela²², Laudria Stella Eryvinka²³, Bunga Citta Nirmala²⁴, Esensi Tarian Geometri²⁵, Abirafdi Amajida Darutama²⁶, Anisa Adityarini Kuswandani²⁷, Lestari²⁸, Sri Handayani Irianingsih²⁹, Siti Khoiriyah³⁰, Ina Lestari³¹, Nur Rahmi Ananda³², Eggi Arguni³³, Titik Nuryastuti³⁴, Tri Wibawa³⁵, on behalf of the Yogyakarta-Central Java COVID-19 study group

¹Pediatric Surgery Division, Department of Surgery/Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; drgunadi@ugm.ac.id

²Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; m.s.hakim@ugm.ac.id

³Disease Investigation Center, Wates, Yogyakarta, Ministry of Agriculture Indonesia; hendra.wibawa@pertanian.go.id

⁴Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; marcelluskorompis@gmail.com

24 ⁵National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia;
25 vivisetiawaty@hotmail.com

26 ⁶National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia;
27 slamet_basir@yahoo.com

28 ⁷Pulmonology Division, Department of Internal Medicine, Faculty of Medicine, Public Health
29 and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia;
30 ika.interna@gmail.com

31 ⁸Centre of Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas
32 Gadjah Mada, Yogyakarta, Indonesia; endah.supriyati@worldmosquito.org

33 ⁹Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health
34 and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, 55281, Indonesia;
35 dr.riat@yahoo.co.id

36 ¹⁰Department of Child Health/Genetics Working Group, Faculty of Medicine, Public Health and
37 Nursing, Universitas Gadjah Mada/ UGM Academic Hospital, Yogyakarta, Indonesia;
38 kristy.iskandar@mail.ugm.ac.id

39 ¹¹Department of Computer Science and Electronics Faculty of Mathematics and Natural
40 Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia; afia@ugm.ac.id

41 ¹²Department of Physiology, Faculty of Medicine, Public Health and Nursing, Universitas
42 Gadjah Mada/UGM Academic Hospital, Yogyakarta, Indonesia; sis12@ugm.ac.id

43 ¹³Balai Besar Teknik Kesehatan Lingkungan dan Pengendalian Penyakit, Yogyakarta,
44 Yogyakarta, Indonesia; irenepunya@gmail.com

45 ¹⁴Department of Anatomical Pathology/Genetics Working Group, Faculty of Medicine, Public
46 Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; nungki@ugm.ac.id

47 ¹⁵Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas
48 Gadjah Mada/UGM Academic Hospital, Yogyakarta, Indonesia; m.edwin.d@ugm.ac.id

49 ¹⁶Department of Pharmacology and Therapy/Genetics Working Group, Faculty of Medicine,
50 Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia;
51 dwi.aris.a@ugm.ac.id

52 ¹⁷Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public
53 Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, 55281,
54 Indonesia; yunika_puspadewi@yahoo.com

55 ¹⁸Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
56 Mada, Yogyakarta, Indonesia; raden.ajeng.d@mail.ugm.ac.id

57 ¹⁹Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
58 Mada, Yogyakarta, Indonesia; irene.tania@mail.ugm.ac.id

59 ²⁰Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
60 Mada, Yogyakarta, Indonesia; khanza.adzkia.v@mail.ugm.ac.id

61 ²¹Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
62 Mada, Yogyakarta, Indonesia; muhammadbustun@gmail.com

63 ²²Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
64 Mada, Yogyakarta, Indonesia; gabriela_christy@ymail.com

65 ²³Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
66 Mada, Yogyakarta, Indonesia; laudriastella@gmail.com

67 ²⁴Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
68 Mada, Yogyakarta, Indonesia; bunga.citta.n@mail.ugm.ac.id

- 69 ²⁵Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
70 Mada, Yogyakarta, Indonesia; esensi.tarian.g@mail.ugm.ac.id
- 71 ²⁶Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
72 Mada, Yogyakarta, Indonesia; abirafdidarutama@gmail.com
- 73 ²⁷Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah
74 Mada, Yogyakarta, Indonesia; anisaadityarini31@gmail.com
- 75 ²⁸Disease Investigation Center, Wates, Yogyakarta, Ministry of Agriculture Indonesia;
76 lestari.dvm@gmail.com
- 77 ²⁹Disease Investigation Center, Wates, Yogyakarta, Ministry of Agriculture Indonesia;
78 shirianingsih@gmail.com
- 79 ³⁰RSUD Dr. Loekmono Hadi, Kudus, Central Java, Indonesia; khoirsiti10@gmail.com
- 80 ³¹RSUD Dr. Loekmono Hadi, Kudus, Central Java, Indonesia; inaleswidodo15@gmail.com
- 81 ³²Pulmonology Division, Department of Internal Medicine, Faculty of Medicine, Public Health
82 and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia;
83 nur.rahmi@mail.ugm.ac.id
- 84 ³³Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas
85 Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia; eggiarguni@ugm.ac.id
- 86 ³⁴Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas
87 Gadjah Mada, Yogyakarta, Indonesia; t.nuryastuti@ugm.ac.id
- 88 ³⁵Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas
89 Gadjah Mada, Yogyakarta, Indonesia; twibawa@ugm.ac.id
- 90
- 91 *Running title: Is Delta variant associated with COVID-19 outcomes?*

92

93   ***Address all correspondence to:**

94   Gunadi, MD, Ph.D.

95   Genetics Working Group

96   Pediatric Surgery Division, Department of Surgery

97   Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital

98   Jl. Kesehatan No. 1 Yogyakarta 55281, Indonesia

99   drgunadi@ugm.ac.id

Abstract

Background: SARS-CoV-2 Delta variant (B.1.617.2) has been responsible for the current increase in COVID-19 infectivity rate worldwide. We compared the impact of the Delta variant and non-Delta variant on the COVID-19 outcomes in patients from Yogyakarta and Central Java provinces, Indonesia.

Methods: We ascertained 161 patients, 69 with the Delta variant and 92 with the non-Delta variant. The Illumina MiSeq next-generation sequencer was used to perform the whole genome sequences of SARS-CoV-2.

Results: The mean age of patients with Delta and the non-Delta variant was 27.3 ± 20.0 and 43.0 ± 20.9 ($p=3 \times 10^{-6}$). The patients with Delta variant consisted of 23 males and 46 females, while the patients with the non-Delta variant involved 56 males and 36 females ($p=0.001$). The Ct value of the Delta variant (18.4 ± 2.9) was significantly lower than the non-Delta variant (19.5 ± 3.8) ($p=0.043$). There was no significant difference in the hospitalization and mortality of patients with Delta and non-Delta variants ($p=0.80$ and 0.29 , respectively). None of the prognostic factors was associated with the hospitalization, except diabetes with an OR of 3.6 (95% CI=1.02-12.5; $p=0.036$). Moreover, the patients with the following factors have been associated with higher mortality rate than patients without the factors: age ≥ 65 years, obesity, diabetes, hypertension, and cardiovascular disease with the OR of 11 (95% CI=3.4-36; $p=8 \times 10^{-5}$), 27 (95% CI=6.1-118; $p=1 \times 10^{-5}$), 15.6 (95% CI=5.3-46; $p=6 \times 10^{-7}$), 12 (95% CI=4-35.3; $p=1.2 \times 10^{-5}$), and 6.8 (95% CI=2.1-22.1; $p=0.003$), respectively. Multivariate analysis showed that age ≥ 65 years, obesity, diabetes, and hypertension were the strong prognostic factors for the mortality of COVID-19 patients with the OR of 3.6 (95% CI=0.58-21.9; $p=0.028$), 16.6 (95%

CI=2.5-107.1; $p=0.003$), 5.5 (95% CI=1.3-23.7; $p=0.021$), and 5.8 (95% CI=1.02-32.8; $p=0.047$), respectively.

Conclusions: We show that the patients infected by the SARS-CoV-2 Delta variant have a lower Ct value than the patients infected by the non-Delta variant, implying that the Delta variant has a higher viral load, which might cause a more transmissible virus among humans. However, the Delta variant does not affect the COVID-19 outcomes in our patients. Our study also confirms the older age and comorbidity increase the mortality rate of COVID-19 patients.

Keywords: COVID-19 outcomes; comorbidity; Ct value; Delta variant; hospitalization; mortality; SARS-CoV-2; viral load; whole genome sequencing

Introduction

The SARS-CoV-2 variants of concern (VOC), including Alpha, Beta, Gamma, and Delta, has attracted public health authorities due to its capability on higher transmission, the possibility of affecting COVID-19 severity, and the impact of the effectiveness of public health measures, diagnosis, treatment, and vaccines [1,2,3]. SARS-CoV-2 Delta variant (B.1.617.2) has been responsible for the current increase in COVID-19 infectivity rate worldwide [4, 5, 6,7].

However, our knowledge about the role of the Delta variant on the COVID-19 outcomes is still very limited [8, 9]. Moreover, several prognostic factors have been associated with COVID-19 illness [10,11,12]. Here, we compared the impact of the Delta variant and non-Delta variant on the COVID-19 outcomes in patients from Yogyakarta and Central Java provinces, Indonesia.

Material and Methods

Patients

We ascertained 161 COVID-19 patients from Yogyakarta and Central Java provinces, 79 males and 82 females. The outcomes of COVID-19 patients were hospitalization and mortality. The Ethics Committee the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital approved our study (KE/FK/0563/EC/2020).

Prognostic Factors

According to previous studies, we associated the following prognostic factors with the hospitalization and mortality of COVID-19 patients: sex, age, comorbidity, and smoking [10,11,12].

SARS-CoV-2 whole-genome sequencing

First, Single-stranded cDNA was synthesized from RNA extracted from the viral transport medium of patients with COVID-19 using SuperScript™ III First-Strand Synthesis System (Thermo Fisher Scientific, MA, United States). Then, the second strand was synthesized using COVID-19 ARTIC v3 primer pool design by SARS-CoV-2 ARTIC Network using Phusion™ High-Fidelity DNA Polymerase (Thermo Fisher Scientific, MA, United States). The library preparations were performed using the Illumina DNA Prep (Illumina, California, United States). The Illumina MiSeq next-generation sequencer was used to perform the whole genome sequences of SARS-CoV-2. The assembly of our sample genomes was mapped into the reference genome from Wuhan, China (hCoV-19/Wuhan/Hu-1/2019, GenBank accession number: NC_045512.2) using Burrow-Wheeler Aligner (BWA) algorithm embedded in UGENE v. 1.30 [13].

Phylogenetic study

We used a dataset of 250 available SARS-CoV-2 genomes extracted from GISAID from our region and others (Acknowledgment Table is provided in Supp. Table 1) to reconstruct the phylogenetic tree. Multiple nucleotide sequence alignment was performed using the MAFFT program (<https://mafft.cbrc.jp/alignment/server/>). We used the neighbor-joining statistical method with 1,000 bootstrap replications [14,15] to construct a phylogenetic tree from 29,420 nucleotide length of the open reading frame (ORF) of SARS-CoV-2, followed by computation of the evolutionary distances and model the rate variation among sites by the Kimura 2-parameter method and the gamma distribution with estimated shape parameter (α) for the dataset,

respectively [16]. We used the DAMBE version 7 [17] to calculate the estimation of the α gamma distribution, MEGA version 10 (MEGA X) [18] for phylogenetic reconstruction, and FigTree to visualize the Newick tree output from MEGA X.

Statistical analysis

We presented data as mean $\pm$ SD and frequency (percentage). Chi-square or Fisher exact tests with 95% confidence interval (CI) were used to find any significant association between independent variables and COVID-19 outcomes. A logistic regression test was used for multivariate analysis. The p -value of <0.05 was considered significant.

Results

Phylogenetic analysis

Phylogenetic analysis showed that about 42.86% of SARS-CoV-2 collected from Central Java and Yogyakarta provinces belonged to B.1.617.2 lineage (Delta variant), while 57.14% clustered in 14 different lineages based on the Pango nomenclature (B, B.1, B.1.1, B.1.459, B.1.456, B.1.459, B.1.462, B.1.466.2, B.1.468, B.1.470, B.1.570, B.1.1.236, B.1.36.19, B.1.1.398) and seven virus samples were not belonging to any of Pango lineages. They are called "none" (Fig.1). Except for Delta variants, none of the virus samples collected from our study belonged to any VOC or variant of interest (VOI) according to WHO labels for naming SARS-CoV-2 variants. However, we found that about 13.04% of virus samples from Central Java and Yogyakarta provinces were clustered into B.1.466.2 lineage (Fig.1) that is currently designated by WHO as a variant of alert for further monitoring.

Characteristics of COVID-19 patients

The mean age of patients with Delta and the non-Delta variant was 27.3 ± 20.0 and 43.0 ± 20.9 ($p=3 \times 10^{-6}$). The patients with the Delta variant consisted of 23 males and 46 females, while the patients with the non-Delta variant involved 56 males and 36 females ($p=0.001$). The Ct value of the Delta variant (18.4 ± 2.9) was significantly lower than the non-Delta variant (19.5 ± 3.8) ($p=0.043$ (Table 1)).

Table 1. Characteristics of COVID-19 patients from Yogyakarta and Central Java provinces, Indonesia.

Characteristics	Total (N=161) N (%); mean $\pm$ SD	Delta variant (N=69) N (%); mean $\pm$ SD	Non-Delta variant (N=92) N (%); mean $\pm$ SD	p-value
Ct value	19.1 ± 3.5	18.4 ± 2.9	19.5 ± 3.8	0.043*
Age (years)	36.3 ± 21.9	27.3 ± 20.0	43.0 ± 20.9	3×10^{-6} *
▪ ≥ 65	17 (10.6)	1 (1.4)	16 (17.4)	1×10^{-6} *
▪ < 65	98 (60.9)	35 (50.7)	63 (68.5)	
▪ < 18	46 (28.6)	33 (47.8)	13 (14.1)	
Sex				
▪ Male	79 (49.1)	23 (33.3)	56 (60.9)	0.001*
▪ Female	82 (50.9)	46 (66.7)	36 (39.1)	
Comorbidities				
▪ Obesity	10 (6.2)	3 (4.3)	7 (7.6)	0.51
▪ Diabetes	26 (16.1)	7 (10.1)	19 (20.7)	0.07
▪ Hypertension	22 (13.7)	4 (5.8)	18 (19.6)	0.012*

▪ Cardiovascular disease	15 (9.3)	4 (5.8)	11 (12)	0.18
▪ Chronic kidney disease	2 (1.2)	0	2 (2.2)	0.50
Smoking	5 (3.1)	1 (1.4)	4 (4.3)	0.39

*, significant ($p < 0.05$); SD, standard deviation

Association between independent variables and COVID-19 patients' outcomes

Next, we associated the independent variables with the COVID-19 outcomes, hospitalization, and mortality. There were no significant differences in the hospitalization and mortality of patients with Delta and non-Delta variants ($p = 0.80$ and 0.29 , respectively) (Table 2). None of the prognostic factors was associated with the hospitalization, except comorbidity of diabetes with the OR of 3.6 (95% CI=1.02-12.5; $p = 0.036$) (Table 2). Moreover, the patients with the following factors have been associated with higher mortality rate than patients without these factors: age ≥ 65 years, obesity, diabetes, hypertension, and cardiovascular disease with OR of 11 (95% CI=3.4-36; $p = 8 \times 10^{-5}$), 27 (95% CI=6.1-118; $p = 1 \times 10^{-5}$), 15.6 (95% CI=5.3-46; $p = 6 \times 10^{-7}$), 12 (95% CI=4-35.3; $p = 1.2 \times 10^{-5}$), and 6.8 (95% CI=2.1-22.1; $p = 0.003$), respectively (Table 2).

Table 2. Association between independent variables and of COVID-19 patients' outcomes.

Variables	Hospitalized (N, %)	p -value	OR (95% CI)	Mortality (N, %)	p -value	OR (95% CI)
Delta variant						
▪ Yes (N=69)	50 (72.5)	0.80	1.1 (0.56-2.2)	6 (8.7)	0.29	0.57 (0.21-1.6)
▪ No (N=92)	65 (70.7)			13 (14.1)		
Age						
▪ <65 (N=98)	73 (74.5)	Ref		9 (9.2)	Ref	
▪ ≥ 65 (N=17)	15 (88.2)	0.35	2.5 (0.5-12)	9 (52.9)	8×10^{-5} *	11 (3.4-36)

▪ <18 (N=46)	27 (58.7)	0.05	0.49 (0.23-1.02)	1 (2.2)	0.17	0.22 (0.02-1.78)
Sex						
▪ Male (N=79)	56 (70.9)	0.88	0.94 (0.47-1.8)	13 (16.5)	0.07	2.5 (0.9-6.9)
▪ Female (N=82)	59 (72)			6 (7.3)		
Comorbidity						
a. Obesity						
Yes (N=10)	10 (100)	0.06	9.26 (0.53-161.3)	7 (70)	1x10 ⁻⁵ *	27 (6.1-118)
No (N=151)	105 (69.5)			12 (7.9)		
b. Diabetes						
Yes (N=26)	23 (88.5)	0.036*	3.6 (1.02-12.5)	12 (46.2)	6x10 ⁻⁷ *	15.6 (5.3-46)
No (N=135)	92 (68.1)			7 (5.2)		
c. Hypertension						
Yes (N=22)	21 (95.5)	0.007*	10 (1.3-77)	10 (45.5)	1.2x10 ⁻⁵ *	12 (4-35.3)
No (N=139)	94 (67.6)			9 (6.5)		
d. Cardiovascular disease						
Yes (N=15)	14 (93.3)	0.07	6.23 (0.79-48)	6 (40)	0.003*	6.8 (2.1-22.1)
No (N=146)	101 (69.2)			13 (8.9)		
e. Chronic kidney disease						
Yes (N=2)	2 (100)	1	2.05 (0.1-43.49)	1 (50)	0.22	7.8 (0.46-130)
No (N=159)	113 (71.1)			18 (11.3)		
Smoking						
▪ Yes (N=5)	2 (40)	0.14	0.25 (0.41-1.6)	1 (20)	0.47	1.9 (0.2-18)
▪ No (N=156)	113 (72.4)			18 (11.5)		

*, significant ($p < 0.05$); CI, confidence interval; OR, odds ratio

Multivariate analysis

Subsequently, we performed a multivariate analysis to find an independent factor affecting the COVID-19 outcomes. Multivariate analysis showed that age ≥ 65 years, obesity, diabetes, and hypertension were strong prognostic factors for the mortality of COVID-19 patients with the OR of 3.6 (95% CI=0.58-21.9; $p=0.028$), 16.6 (95% CI=2.5-107.1; $p=0.003$), 5.5 (95% CI=1.3-23.7; $p=0.021$), and 5.8 (95% CI=1.02-32.8; $p=0.047$), respectively. In addition, no prognostic factors were associated with the hospitalization of COVID-19 patients (Table 3).

Table 3. Multivariate analysis of the association between independent variables and COVID patients' outcomes

Variables	Hospitalized		Mortality	
	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
Delta variant	1.3 (0.6-2.8)	0.47	3.6 (0.58-21.9)	0.167
Age (≥ 65 years)	0.7 (0.1-5.1)	0.79	11.5 (1.3-102.6)	0.028*
Sex (male)	0.9 (0.46-2.1)	0.98	3.2 (0.65-16)	0.15
Comorbidity				
▪ Obesity	-	0.99	16.6 (2.5-107.1)	0.003*
▪ Diabetes	1.68 (0.41-6.8)	0.46	5.5 (1.3-23.7)	0.021*
▪ Hypertension	10.4 (0.92-118)	0.058	5.8 (1.02-32.8)	0.047*
▪ Cardiovascular disease	3 (0.3-28.8)	0.32	0.7 (0.08- 6.2)	0.75
▪ Chronic kidney disease	-	0.99	1.2 (0.015-96.6)	0.92
Smoking	0.11 (0.008-1.4)	0.09	0.5 (0.003-74.4)	0.78

*, significant ($p < 0.05$); CI, confidence interval; OR, odds ratio

Discussion

We are able to show that the Ct value of the patients infected by the SARS-CoV-2 Delta variant has a lower Ct value than the patients infected by the non-Delta variant. Our finding is compatible with previous studies [19,20; 21]. Our finding supports that the higher viral load of the Delta variant results in its characteristic of being more transmissible among humans [19,22]. It is associated with a higher reproductive number (R_0) of the Delta variant ($R_0=7$) than the parental SARS-CoV-2 and the Alpha variant [23]. In addition, the Delta variant also has a significantly longer duration (18 days) of Ct value ≤ 30 than the original strain (13 days) [20]. Again, this evidence implies higher transmissibility of the Delta variant than other strains.

We also show that the Delta variant is not associated with the mortality and hospitalization of COVID-19 patients. Our findings are different from previous reports [8,20,24]. Sheikh *et al.* [2021] showed that the risk of hospitalization is twice higher in patients with Delta variant than Alpha variant. Fisman *et al.* [2021] revealed that the risk of hospitalization, admission of ICU, and mortality is significantly higher in the Delta variant than in N501Y-positive variants. They suggested that the Delta variant is more virulent than previous VOCs [24]. Ong *et al.* [2021] showed that the patients with the Delta variant showed more severe COVID-19 than the original variant. These differences might be due to differences in the host's genetic background [25]. They identified a novel susceptibility locus for severe COVID-19 at 3p21.31 gene cluster, consisting of *SLC6A20*, *LZTFL1*, *CCR9*, *FYCO1*, *CXCR6*, and *XCRI1*, that their functions are related to COVID-19 [25]. Further study is necessary to identify the genetic susceptibility locus for severe COVID-19 in our patients. Another difference between our study

and previous reports is that we compared the outcomes of the Delta variant and non-VOC, while other reports compared the Delta variant and other VOCs [8; 24].

Interestingly, approximately 50% of Delta variant infected children, higher than non-Delta variant (~15%). Similar findings were reported by a previous study showing the frequency of Delta variant is higher in aged 5-9 years than non-Delta variant [8]. While the Delta variant infected more females than males, in contrast, the non-Delta variant infected more males than females. However, multivariate analysis did not show an association between sex and COVID-19 outcomes. It is similar to a study by Ong *et al.* [2021]. It should be noted that the impact of sex on the COVID-19 outcomes is still controversial [10,20, 26,27]. While some studies showed that male has a higher risk for severe COVID-19 [10,26], other reports do not support the association [20, 27].

Our findings reveal the older age and comorbidities, including obesity, diabetes, and hypertension, are independent prognostic factors for the mortality of COVID-19 patients. Our findings were similar to previous studies [10, 20,26]. Several mechanisms have been proposed for the increased risk of COVID-19 in diabetes patients, including an elevated level of ACE-2 receptors and furin, and dysregulated immune response, while the following factors contribute for the obesity to be associated with the worse prognosis of COVID-19: the compromised ventilation at the base of the lung and immune response [28]. The use of the antihypertension drug, particularly ACE-2 inhibitors and angiotensin receptor blockers, is associated with the upregulated expression of the ACE-2 receptor, resulting in a higher possibility of respiratory failure [28]. Unfortunately, we do not have complete data on the use of ACE-2 inhibitors and angiotensin receptor blockers in our patients. Therefore, it is challenging to conclude that the increased mortality of COVID-19 in hypertension patients is due to antihypertension.

Our retrospective design and small sample size were the weakness of our study.

Moreover, we only determined the impact of Delta variant and some comorbidities on the COVID-19 outcomes by overall means without considering other variables affecting the data, including other mutations in the SARS-CoV-2 genome and vaccination history.

Conclusions

We show that the patients infected by the SARS-CoV-2 Delta variant have a lower Ct value than the patients infected by the non-Delta variant, implying that the Delta variant has a higher viral load, which might cause a more transmissible virus among humans. However, the Delta variant does not affect the COVID-19 outcomes in our patients. Our study also confirms that older age and comorbidity increase the mortality rate of COVID-19 patients.

List of abbreviations

CI, confidence interval; OR, odds ratio; VOC, variant of concern

Declarations

Ethics approval and consent to participate

This study was approved by the Medical and Health Research Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia (KE/FK/0563/EC/2020). The research has been performed following the Declaration of Helsinki. All participants or guardians signed written informed consent for participating in this study.

303 *Consent to publish*

304 Not applicable.

305

306 *Availability of data and material*

307 All data generated or analyzed during this study are included in the submission. The sequence
308 and metadata are shared through GISAID (www.gisaid.org).

309

310 *Competing interests*

311 The authors declared no potential conflicts of interest concerning this article's research,
312 authorship, and/or publication.

313

314 *Funding*

315 The Ministry of Education, Culture, Research and Technology, Indonesia, funded our study. The
316 funders had no role in study design, data collection, and analysis, decision to publish, or
317 manuscript preparation.

318

319 *Authors' contributions*

320 G, KI, and NA conceived the study. G drafted the manuscript, and MSH, HW, and TW critically
321 revised the manuscript for important intellectual content. M, DAP, ITa, KAV, MBA, GCG, LSE,
322 BCN, ETG, AAD, AAK, L, and SHI performed the library preparation and NGS. G, MSH, M,
323 VS, SI, IT, ES, REK, KI, A, S, I, NA, EWD, DAAN, YP, SK, IL, NRA, EA, TN, and TW
324 collected the data; and G, MSH, HW, and M analyzed the data. All authors have read and
325 approved the manuscript and agreed to be accountable for all aspects of the work in ensuring that

questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Acknowledgments

We thank the Collaborator Members of the Yogyakarta-Central Java COVID-19 study group:

Eko Budiono, Heni Retnowulan, Sumardi, Bambang Sigit Riyanto, Munawar Gani, Satria Maulana, Ira Puspitawati, Osman Sianipar (Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada [FK-KMK UGM]/RSUP Dr. Sardjito), Bagoes Poermadjaja (Balai Besar Veteriner Wates, Yogyakarta), Indaryati and Havid Setyawan (Balai Besar Teknik Kesehatan Lingkungan dan Pengendalian Penyakit, Yogyakarta), Ludhang Pradipta Rizki and Sri Fatmawati (FK-KMK UGM), Safitriani and Muhammad Taufiq Soekarno (PT. Pandu Biosains).

We gratefully acknowledge the authors, the originating and submitting laboratories for their sequence and metadata shared through GISAID. We also thank to Besar Besar Veteriner Wates (Disease Investigation Center Wates) where the virus samples were sequenced using the NGS Illumina MiSeq instrument. All submitters of data may be contacted directly via www.gisaid.org. The Acknowledgments Table for GISAID is reported as Supplementary Table 1.

References

1. World Health Organization. Tracking SARS-CoV-2 variants.
<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> Accessed on August 16, 2021.
2. World Health Organization. Weekly epidemiological update on COVID-19 - 10 August 2021. <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19--10-august-2021> Accessed on August 16, 2021.
3. Gushchin VA, Dolzhikova IV, Shchetinin AM, Odintsova AS, Siniavin AE, Nikiforova MA, et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. *Vaccines* (Basel). 2021;9(7):779.
4. Herlihy R, Bamberg W, Burakoff A, Alden N, Severson R, Bush E, Kawasaki B, Berger B, Austin E, Shea M, Gabrieloff E, Matzinger S, Burdorf A, Nichols J, Goode K, Cilwick A, Stacy C, Staples E, Stringer G. Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - Mesa County, Colorado, April-June 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(32):1084-1087.
5. Kadri SS, Simpson SQ. Potential Implications of SARS-CoV-2 Delta Variant Surges for Rural Areas and Hospitals. *JAMA*. 2021 Aug 12. DOI: 10.1001/jama.2021.13941.
6. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. *Euro Surveill* 2021; 26: 2100509.
7. Musser JM, Christensen PA, Olsen RJ. et al. Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas.

medRxiv. 2021 Jul 22;

<https://www.medrxiv.org/content/10.1101/2021.07.19.21260808v1.full-text>

8. Sheikh A, McMenamin J, Taylor B, Robertson C; Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet*. 2021;397(10293):2461-2462.
9. Shah SA, Moore E, Robertson C, McMenamin J, Katikireddi SV, Simpson CR, Shi T, Agrawal U, McCowan C, Stock S, Ritchie LD, Sheikh A; Public Health Scotland and the EAVE II Collaborators. Predicted COVID-19 positive cases, hospitalisations, and deaths associated with the Delta variant of concern, June-July, 2021. *Lancet Digit Health*. 2021:S2589-7500(21)00175-8.
10. Beeching NJ, Fletcher TE, Fowler R. BMJ best practice. Coronavirus Disease 2019 (COVID-19). <https://bestpractice.bmj.com/topics/en-us/3000168/prognosis> Accessed on August 16 2021.
11. Cho Y, Cho Y, Choi HJ, Lee H, Lim TH, Kang H, Ko BS, Oh J. The effect of BMI on COVID-19 outcomes among older patients in South Korea: a nationwide retrospective cohort study. *Ann Med*. 2021;53(1):1292-1301.
12. Zhou B, Kojima S, Kawamoto A, Fukushima M. COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. *J Med Virol*. 2021;93(5):2694-2704.
13. About UGENE - Unipro UGENE Online User Manual v. 1.30 - WIKI [Internet]. Ugene.net. 2020 [cited 22 December 2020]. Available from: <https://ugene.net/wiki/display/UUOUM30/About+UGENE>.

14. Saitou N. and Nei M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. *Molecular Biology and Evolution*. 1997;4:406-425.
15. Felsenstein J. Confidence limits on phylogenies: An approach using the bootstrap. *Evolution*. 1985;39:783-791.
16. Kimura M. A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. *Journal of Molecular Evolution*. 1980;16:111-120.
17. Xia X. DAMBE7: New and improved tools for data analysis in molecular biology and evolution. *Mol Biol Evol*. 2018;35:1550–1552.
18. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms. *Mol Biol Evol*. 2018;35:1547-1549
19. Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, et al. Viral infection and transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant. *medRxiv* 2021.07.07.21260122; DOI: <https://doi.org/10.1101/2021.07.07.21260122>
20. Ong SWX, Chiew CJ, Ang LW, et al. Clinical and Virological Features of SARS-CoV-2 Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). *SSRN Journal*. 2021 Jun 7; <https://doi.org/10.2139/ssrn.3861566>
21. Mlcochova P, Kemp S, Dhar S, et al. SARS-CoV-2 B.1.617.2 Delta Variant Emergence and Vaccine Breakthrough. *Research Square Platform LLC*. 2021 Jun 22; DOI:10.21203/rs.3.rs-637724/v1
22. Callaway E. Delta coronavirus variant: scientists brace for impact. *Nature*. 2021;595(7865):17-18.

23. Burki TK. Lifting of COVID-19 restrictions in the UK and the Delta variant. *Lancet Respir Med.* 2021;9(8):e85.
24. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada. *medRxiv.* 2021 Jul 12; <https://doi.org/10.1101/2021.07.05.21260050>
25. Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med.* 2020;383(16):1522-1534.
26. Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. *PLoS One.* 2021;16(3):e0248281.
27. Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. *medRxiv.* 2021 Jul 31; <https://www.medrxiv.org/content/10.1101/2021.07.28.21261295v1>
28. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KOA, Ahmed Z, Younas S. COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health.* 2020;13(12):1833-1839.

Figure Legend

Figure 1. (a) The evolutionary history was inferred using the Neighbor-Joining method conducted in MEGA-X. The evolutionary distances were computed using the Kimura 2-parameter method with 1000 bootstrap replication and are in the units of the number of base substitutions per site (0.0001) shown in the bottom tree. This analysis involved 250 nucleotide sequences with a total of 29,420 positions in the final dataset and all ambiguous positions were

433 removed for each sequence pair (pairwise deletion option). The Delta variant taxa are indicated
434 in blue line, whereas non-Delta variant taxa appeared in green line. (b) A pie chart illustrates the
435 proportion of Delta variant and non-Delta samples detected in the present study.